Taken together, our data suggest that miR-34a inhibitor treatment improves the alveolar and vascular development in the hyperoxia-exposed BPD mouse model, at least in part, via the Ang1/Tie signaling pathway. The gene discussed is ANGPT1; the disease is bronchopulmonary dysplasia.